Comparing 5% Dextrose Injections Into or Around Partial Supraspinatus Tendon Tears
Intralesional Versus Perilesional 5% Dextrose Injection for Partial Supraspinatus Tendon Tears: A Randomized Controlled Trial
This prospective, single-center randomized trial compared ultrasound-guided intralesional and perilesional 5% dextrose injections in adults with partial supraspinatus tendon tears. Participants and outcome assessors were blinded to group assignment. Forty-six participants were randomized equally to the two groups, and 40 completed follow-up and were included in the final analysis (20 per group).
Both groups received ultrasound-guided injections at baseline and at study weeks 3 and 6. At each session, both groups received a 5% dextrose injection at the supraspinatus tendon attachment. An additional injection was given either directly into the tear or into the tendon tissue around it, depending on group assignment. Both groups began the same home exercise program after the first injection.
Shoulder pain, disability, and health-related quality of life were assessed at baseline and at study weeks 9 and 12. Tear dimensions and supraspinatus tendon thickness were measured by ultrasonography at baseline and at study week 12.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
This prospective, single-center, parallel-group randomized trial enrolled adults aged 18 to 75 years with symptomatic partial supraspinatus tendon tears. An independent researcher generated the 1:1 allocation sequence using a computer-based random number generator. Allocation was concealed in sequentially numbered, opaque, sealed envelopes. The injecting physician opened the envelopes after the baseline clinical and ultrasonographic assessments. Participants and outcome assessors were blinded to group assignment.
Both groups received three ultrasound-guided 5% dextrose injection sessions at baseline and at study weeks 3 and 6. At each session, 2 mL was distributed across three points at the supraspinatus tendon enthesis in both groups. An additional 2 mL was injected into the tendon defect in the intralesional group or into the tendon tissue surrounding the defect in the perilesional group using a peppering technique. The total injection volume was 4 mL per session in both groups. Participants began the same standardized home exercise program after the first injection and were instructed to perform it twice daily throughout the study.
Clinical outcomes were assessed at baseline and at study weeks 9 and 12. Mean daytime pain, worst daytime pain, and night pain were recorded separately using the Numeric Rating Scale. Shoulder pain and disability were assessed using the Shoulder Pain and Disability Index, and health-related quality of life was assessed using the 12-Item Short Form Health Survey. Short-axis and long-axis defect diameters and supraspinatus tendon thickness were measured by ultrasonography at baseline and at study week 12.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Ankara, Tyrkiet (Türkiye)
- Ankara Bilkent City Hospital, Physical Medicine and Rehabilitation Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age 18 to 75 years
- Shoulder pain and functional limitation for at least 3 months
- Partial supraspinatus tendon tear identified on magnetic resonance imaging performed within the previous 6 months and confirmed by ultrasonography at study entry. Articular-sided, bursal-sided, and intrasubstance tears were eligible.
- At least one positive Neer, Hawkins-Kennedy, or painful arc test
- Ability to attend follow-up visits
- Written informed consent to participate
For participants with bilateral involvement, only the more painful shoulder was included.
Exclusion Criteria:
- - Full-thickness supraspinatus tendon tear
- Major pathology of rotator cuff tendons other than the supraspinatus
- Advanced acromioclavicular or glenohumeral osteoarthritis
- Marked adhesive capsulitis
- Previous shoulder surgery
- Corticosteroid, platelet-rich plasma, or prolotherapy injection into the affected shoulder within the previous 3 months
- Active infection, including infection at the injection site
- Skin lesion at the injection site
- Bleeding diathesis or anticoagulant use
- Known allergy or intolerance to dextrose
- Uncontrolled diabetes mellitus (HbA1c >8.5%)
- Severe endocrine or metabolic disease
- Immunosuppression
- Rheumatologic disease involving the shoulder
- Neurological disease affecting shoulder function
- Pregnancy
- Active malignancy
- Cognitive impairment preventing reliable completion of questionnaires
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Intralesional 5% Dextrose Injection
Participants received three ultrasound-guided 5% dextrose injection sessions at baseline and at study weeks 3 and 6. At each session, dextrose was injected at the supraspinatus tendon enthesis and directly into the partial tendon tear. Participants began the same standardized home exercise program as the perilesional group after the first injection. |
At each ultrasound-guided session, 2 mL of 5% dextrose was distributed across three points at the supraspinatus tendon enthesis. An additional 2 mL was injected directly into the partial tendon defect using a peppering technique. The total volume was 4 mL per session. |
|
Aktiv komparator: Perilesional 5% Dextrose Injection
Participants received three ultrasound-guided 5% dextrose injection sessions at baseline and at study weeks 3 and 6. At each session, dextrose was injected at the supraspinatus tendon enthesis and into the tendon tissue surrounding the margins of the partial tear. Participants began the same standardized home exercise program as the intralesional group after the first injection. |
At each ultrasound-guided session, 2 mL of 5% dextrose was distributed across three points at the supraspinatus tendon enthesis. An additional 2 mL was injected into the tendon tissue surrounding the margins of the partial tear using a peppering technique. The total volume was 4 mL per session. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Shoulder Pain Intensity Assessed by Numeric Rating Scale
Tidsramme: Baseline and study weeks 9 and 12.
|
Mean daytime shoulder pain, worst daytime shoulder pain, and night pain were assessed separately using an 11-point Numeric Rating Scale (NRS). Each score ranged from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicated greater pain intensity. |
Baseline and study weeks 9 and 12.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Shoulder Pain and Disability Assessed by the Shoulder Pain and Disability Index
Tidsramme: Baseline and study weeks 9 and 12.
|
The Shoulder Pain and Disability Index (SPADI) was used to assess shoulder pain and disability. The pain subscale contains 5 items, and the disability subscale contains 8 items. The two subscales were scored separately on a 0-100 scale. Higher scores indicated greater pain or disability. |
Baseline and study weeks 9 and 12.
|
|
Change in Health-Related Quality of Life Assessed by the Short Form-12 Health Survey
Tidsramme: Baseline and study weeks 9 and 12.
|
Health-related quality of life was assessed using the 12-Item Short Form Health Survey (SF-12). The Physical Component Summary (PCS) and Mental Component Summary (MCS) scores were calculated separately. Higher scores indicated better health-related quality of life in the corresponding component. |
Baseline and study weeks 9 and 12.
|
|
Change in Supraspinatus Tendon Thickness Assessed by Ultrasonography
Tidsramme: Baseline and study week 12.
|
Supraspinatus tendon thickness was measured in millimeters using shoulder ultrasonography with a 5-12 MHz linear transducer. |
Baseline and study week 12.
|
|
Change in Partial Rotator Cuff Defect Size Assessed by Ultrasonography
Tidsramme: Baseline and study week 12.
|
The short-axis and long-axis diameters of the partial supraspinatus tendon tear were measured separately in millimeters using electronic calipers on the ultrasound images that best displayed the defect. |
Baseline and study week 12.
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: ESRA Ülgen Kıratlıoğlu, Ankara City Hospital Bilkent
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- E2-26-14590
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Individual participant data will not be shared due to privacy and ethical restrictions.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .